IN2014MN01879A - - Google Patents

Info

Publication number
IN2014MN01879A
IN2014MN01879A IN1879MUN2014A IN2014MN01879A IN 2014MN01879 A IN2014MN01879 A IN 2014MN01879A IN 1879MUN2014 A IN1879MUN2014 A IN 1879MUN2014A IN 2014MN01879 A IN2014MN01879 A IN 2014MN01879A
Authority
IN
India
Prior art keywords
antibodies
antibody chains
derivatives
chimaeric
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Allan Bradley
E Chiang Lee
Qi Liang
Wei Wang
Dominik Spensberger
Hui Liu
Jasper Clube
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/433,084 external-priority patent/US9445581B2/en
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of IN2014MN01879A publication Critical patent/IN2014MN01879A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1239—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Vibrionaceae (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN1879MUN2014 2012-03-28 2013-03-18 IN2014MN01879A (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/433,084 US9445581B2 (en) 2012-03-28 2012-03-28 Animal models and therapeutic molecules
US13/434,361 US9253965B2 (en) 2012-03-28 2012-03-29 Animal models and therapeutic molecules
PCT/GB2013/050682 WO2013144566A2 (en) 2012-03-28 2013-03-18 Animal models and therapeutic molecules

Publications (1)

Publication Number Publication Date
IN2014MN01879A true IN2014MN01879A (pl) 2015-07-03

Family

ID=47913490

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1879MUN2014 IN2014MN01879A (pl) 2012-03-28 2013-03-18

Country Status (13)

Country Link
US (7) US9253965B2 (pl)
EP (3) EP2785845A2 (pl)
JP (4) JP6336435B2 (pl)
CN (1) CN104334732B (pl)
AU (1) AU2013239501B2 (pl)
CA (1) CA2867530A1 (pl)
DK (1) DK2831244T3 (pl)
ES (1) ES2979344T3 (pl)
HK (1) HK1200872A1 (pl)
IN (1) IN2014MN01879A (pl)
NZ (1) NZ629202A (pl)
SG (1) SG11201405058WA (pl)
WO (2) WO2013061098A2 (pl)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5087625B2 (ja) 2006-09-01 2012-12-05 セラピューティック・ヒューマン・ポリクローナルズ・インコーポレーテッド 非ヒトトランスジェニック動物におけるヒトまたはヒト化免疫グロブリンの発現強化
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CA2806233C (en) 2010-07-26 2021-12-07 Trianni, Inc. Transgenic animals and methods of use
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
NZ606824A (en) 2010-08-02 2015-05-29 Regeneron Pharma Mice that make binding proteins comprising vl domains
PL2578688T5 (pl) 2011-02-25 2023-05-29 Regeneron Pharmaceuticals, Inc. Myszy adam6
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
JP2014533930A (ja) 2011-09-19 2014-12-18 カイマブ・リミテッド 免疫グロブリン遺伝子多様性の操作およびマルチ抗体治療薬
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
SG10202010120XA (en) 2011-10-17 2020-11-27 Regeneron Pharma Restricted immunoglobulin heavy chain mice
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
CA2859408C (en) 2011-12-20 2020-06-16 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
KR102436654B1 (ko) 2012-06-12 2022-08-26 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
LT2840892T (lt) 2013-02-20 2018-07-25 Regeneron Pharmaceuticals, Inc. Nežmogaus tipo gyvūnai su modifikuotomis imunoglobulino sunkiųjų grandinių sekomis
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
SG10201802295XA (en) 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
KR102601491B1 (ko) 2014-03-21 2023-11-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
WO2015153912A1 (en) 2014-04-03 2015-10-08 Igm Biosciences, Inc. Modified j-chain
BR112017018941B8 (pt) 2015-03-04 2023-01-10 Igm Biosciences Inc Molécula de ligação a cd20, seu uso, composição e método in vitro para direcionar a morte mediada por complemento de uma célula que expressa cd20
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
US10618978B2 (en) 2015-09-30 2020-04-14 Igm Biosciences, Inc. Binding molecules with modified J-chain
WO2017059387A1 (en) 2015-09-30 2017-04-06 Igm Biosciences, Inc. Binding molecules with modified j-chain
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
EP3408397B1 (en) 2016-01-27 2020-07-15 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
DK3411476T3 (da) 2016-02-04 2024-07-15 Trianni Inc Forøget produktion af immunoglobuliner
GB2550114A (en) 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists
EP3471753A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 and il-2 cytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN116640214A (zh) 2016-08-09 2023-08-25 科马布有限公司 分离抗体及其应用
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MX2019005256A (es) * 2016-11-04 2019-08-05 Regeneron Pharma Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente.
CN109906030B (zh) 2016-11-04 2022-03-18 安健基因公司 用于产生仅重链抗体的经基因修饰的非人动物和方法
AU2017367695A1 (en) 2016-12-02 2019-06-13 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
EP3574017A1 (en) 2017-01-27 2019-12-04 Kymab Limited Anti-opg antibodies
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
EP3656858A4 (en) * 2017-07-21 2021-04-21 I'rom Group Co., Ltd. POLYNUCLEOTIDE INTENDED TO MODIFY A TARGET SEQUENCE AND ITS USE
WO2019037099A1 (en) * 2017-08-25 2019-02-28 Wenning Qin LARGE SCALE MODIFICATION OF GENOME EUCARYOTE
JP7430636B2 (ja) * 2017-12-05 2024-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
CN108486126A (zh) * 2018-03-27 2018-09-04 重庆金迈博生物科技有限公司 一种核酸分子及其在人源化抗体中的应用
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
MX2021012171A (es) 2019-04-09 2021-12-10 Abcuro Inc Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1).
WO2021003149A1 (en) * 2019-07-01 2021-01-07 Trianni, Inc. Transgenic mammals and methods of use
IL293314A (en) 2019-11-29 2022-07-01 Kymab Ltd Treatment of physiological iron overload
EP4158034A4 (en) 2020-06-02 2024-07-03 Biocytogen Pharmaceuticals Beijing Co Ltd GENETICALLY MODIFIED NON-HUMAN ANIMALS HAVING A LIGHT-CHAIN IMMUNOGLOBULIN LOCUS
CN115988960A (zh) 2020-06-25 2023-04-18 株式会社湖美宝 杂合转基因动物
WO2022026775A1 (en) * 2020-07-30 2022-02-03 Prellis Biologics, Inc Compositions and methods for targeting coronavirus
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
IL303626A (en) 2020-12-16 2023-08-01 Regeneron Pharma Mice expressing human FC alpha receptors
JP2024528877A (ja) 2021-07-26 2024-08-01 アブクロ，インク． キラー細胞レクチン様受容体サブファミリーｇメンバー１（ｋｌｒｇ１）枯渇性抗体
WO2024155604A1 (en) * 2023-01-18 2024-07-25 Gilead Sciences, Inc. Chimeric transgenic immunoglobulin mice with an altered heavy chain locus and methods of making and using same
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US4720449A (en) 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
ATE158021T1 (de) * 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5859307A (en) 1992-02-04 1999-01-12 Massachusetts Institute Of Technology Mutant RAG-1 deficient animals having no mature B and T lymphocytes
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
DE4228162C1 (de) 1992-08-25 1994-01-13 Rajewsky Klaus Dr Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
US5565321A (en) 1993-01-22 1996-10-15 Immunex Corporation Detection of mutations in a CD40 ligand gene
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
DE4331162A1 (de) 1993-09-14 1995-03-16 Bayer Ag Verfahren zur Herstellung von Cyaninfarbstoffen
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU3507297A (en) 1996-06-26 1998-01-14 Baylor College Of Medicine Chromosomal rearrangement by insertion of two recombination substrates
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
NZ504300A (en) 1997-11-18 2002-06-28 Pioneer Hi Bred Int A method for directional stable transformation of eukaryotic cells using non-identical recombination sites
ES2337027T3 (es) 1997-12-05 2010-04-20 Europaisches Laboratorium Fur Molekularbiologie (Embl) Nuevo metodo de clonacion de dna basado en el sistema de recombinacion rece-rect de e. coli.
EP0939120A1 (en) 1998-02-27 1999-09-01 Gesellschaft für biotechnologische Forschung mbH (GBF) Method for marker-free repetitive DNA expression cassette exchange in the genome of cells or parts of cells
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6355412B1 (en) 1999-07-09 2002-03-12 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2307503A1 (en) 2000-05-02 2001-11-02 Carlos F. Barbas Iii Peptides for use as a vaccine or treatment for hiv infection
IL154063A0 (en) 2000-07-21 2003-07-31 Us Agriculture Methods for the replacement, translocation and stacking of dna in eukaryotic genomes
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ATE503012T1 (de) 2000-11-17 2011-04-15 Kyowa Hakko Kirin Co Ltd Expression von xenogenen (humanen) immunglobulinen in klonierten, transgenen huftieren
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
AU2002246733B2 (en) 2000-12-19 2007-09-20 Altor Bioscience Corporation Transgenic animals comprising a humanized immune system
PL228041B1 (pl) 2001-01-05 2018-02-28 Amgen Fremont Inc Przeciwciało przeciwko receptorowi insulinopodobnego czynnika wzrostu I, zawierajaca go kompozycja farmaceutyczna, sposób jego wytwarzania, zastosowania, linia komórkowa, wyizolowana czasteczka kwasu nukleinowego, wektor, komórka gospodarza oraz zwierze transgeniczne.
FR2827302B1 (fr) 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
WO2003031656A1 (en) 2001-10-05 2003-04-17 United States Environmental Protection Agency Genetic testing for male factor infertility
EP3269235B1 (en) 2001-11-30 2022-01-26 Amgen Fremont Inc. Transgenic mice bearing human ig lambda light chain genes
US20050095712A1 (en) 2002-01-17 2005-05-05 Alberto Martin Mutations caused by activation-induced cytidine deaminase
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
WO2004022738A1 (en) 2002-09-09 2004-03-18 California Institute Of Technology Methods and compositions for the generation of humanized mice
DE10251918A1 (de) 2002-11-08 2004-05-19 Horn, Carsten, Dipl.-Biochem. Dr. Systeme zur Erzeugung stabiler genomischer Transgen-Insertionen
US7700356B2 (en) 2002-11-08 2010-04-20 The United States Of America As Represented By The Secretary Of Agriculture System for gene targeting and producing stable genomic transgene insertions
AR042145A1 (es) 2002-11-27 2005-06-08 Dow Agrociences Llc Produccion de inmunoglobulinas en plantas con una fucocilacion reducida
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US7205148B2 (en) 2003-06-11 2007-04-17 Regeneron Pharmaceuticals, Inc. Genome mutation by intron insertion into an embryonic stem cell genome
GB2403475B (en) 2003-07-01 2008-02-06 Oxitec Ltd Stable integrands
JP2005042792A (ja) 2003-07-28 2005-02-17 Nsk Ltd ローラクラッチ及びローラクラッチ内蔵型プーリ装置
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
WO2005019463A1 (en) 2003-08-11 2005-03-03 Therapeutic Human Polyclonals, Inc. Improved transgenesis with humanized immunoglobulin loci
US7604994B2 (en) 2003-09-03 2009-10-20 Morphotek, Inc. Genetically altered antibody-producing cell lines with improved antibody characteristics
US7205140B2 (en) 2003-10-20 2007-04-17 Campusgen Gmbh Nucleotide sequence for creatinine deiminase and method of use
KR20130133302A (ko) 2003-12-10 2013-12-06 메다렉스, 인코포레이티드 Ｉｐ―１０ 항체 및 그의 용도
AU2005227313A1 (en) 2004-03-19 2005-10-06 Amgen Inc. Reducing the risk of human and anti-human antibodies through V gene manipulation
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
JP2008512987A (ja) 2004-07-22 2008-05-01 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 結合分子
FR2875239B1 (fr) 2004-09-10 2007-07-20 Inst Necker Ass Loi De 1901 Procede pour l'acceleration des mutations somatiques et son application en proteomique
WO2006044492A2 (en) 2004-10-14 2006-04-27 Ingenious Targeting Laboratory, Inc. Methods for generating rat embryo-derived cell lines and genetic modification of rat genome
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
WO2006055704A2 (en) 2004-11-17 2006-05-26 Curagen Corporation Antibodies directed to ten-m proteins and uses thereof
RS52036B (en) 2004-12-21 2012-04-30 Medimmune Limited ANGIOPOETIN-2 ANTIBODIES AND ITS USES
BRPI0520212A2 (pt) 2005-05-14 2009-08-18 Univ Fudan métodos de geração de um vertebrado não humano transgênico, e de uma célula de vertebrado recombinante, célula de vertebrado em cultura, e, ácido nucleico
EP1780272A1 (en) 2005-10-27 2007-05-02 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Method for enhancing somatic hypermutation, gene conversion and class switch recombination
GB0601513D0 (en) 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding molecules 3
KR101481843B1 (ko) 2006-01-25 2015-01-12 에라스무스 유니버시티 메디컬 센터 로테르담 형질전환 동물 내에서의 중쇄만의 항체의 생성
US7462759B2 (en) 2006-02-03 2008-12-09 Pioneer Hi-Bred International, Inc. Brittle stalk 2 gene family and related methods and uses
EP2505058A1 (en) * 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
CA2655344C (en) 2006-06-27 2016-09-13 Vaxdesign Corporation Models for vaccine assessment
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
JP2010501165A (ja) 2006-08-22 2010-01-21 ジーツー インフラメイション プロプライエタリー リミテッド 抗体の作製方法
DK2769992T3 (da) 2006-10-02 2021-03-22 Regeneron Pharma Humane antistoffer med høj affinitet for human IL-4-receptor
WO2008070367A2 (en) 2006-11-01 2008-06-12 Facet Biotech Corporation Mammalian cell-based immunoglobulin display libraries
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
GB0700194D0 (en) 2007-01-05 2007-02-14 Univ Edinburgh Humanisation of animals
EP2126105A4 (en) 2007-02-20 2010-11-03 Anaptysbio Inc SOMATIC HYPERPERMUTATION SYSTEMS
WO2008118970A2 (en) 2007-03-27 2008-10-02 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
GB0706628D0 (en) 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
AU2008259939B2 (en) 2007-06-01 2014-03-13 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
MY147651A (en) 2007-07-31 2012-12-31 Regeneron Pharma Human antibodies to human cd20 and method of using thereof
RU2473564C2 (ru) 2007-08-10 2013-01-27 Ридженерон Фармасьютикалз, Инк. Антитела человека с высокой аффинностью к фактору роста нервов человека
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
JP2009122383A (ja) * 2007-11-14 2009-06-04 Canon Inc 揺動体装置の製造方法、該製造方法により製造された揺動体装置によって構成される光偏向器及び光学機器
NZ586149A (en) 2007-12-10 2012-05-25 Ablexis Llc Methods for sequential replacement of targeted region by homologous recombination
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
CN101978000A (zh) 2008-01-25 2011-02-16 卡伯特公司 制备改性有色颜料的方法
KR101409375B1 (ko) 2008-01-31 2014-06-18 삼성전자주식회사 반도체 메모리장치의 블록 디코딩 회로
WO2009118524A2 (en) 2008-03-26 2009-10-01 Iti Scotland Limited Efficient insertion of dna into embryonic stem cells
US8012714B2 (en) 2008-04-14 2011-09-06 Innovative Targeting Solutions, Inc. Sequence diversity generation in immunoglobulins
KR20110020860A (ko) 2008-05-23 2011-03-03 알리바 바이오파마수티컬스, 아이엔씨. 유전자 삽입동물에서 단일 ｖｌ 도메인 항체를 생산하는 방법
ES2906344T3 (es) 2008-06-27 2022-04-18 Merus Nv Animal murino transgénico productor de anticuerpos
LT2346994T (lt) 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
RU2011129459A (ru) 2008-12-18 2013-01-27 Эрасмус Юниверсити Медикал Сентр Роттердам Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение
WO2010091182A2 (en) 2009-02-04 2010-08-12 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
CN102482639B (zh) 2009-04-03 2016-01-06 医学研究会 活化诱导胞苷脱氨酶(aid)突变体及使用方法
CN102498210B (zh) 2009-06-26 2015-07-29 航道生物技术有限责任公司 替代轻链的表达
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
JP5781508B2 (ja) 2009-07-15 2015-09-24 アイム・セラピューティクス・べー・フェー 高親和性抗体を産生させるための手段および方法
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP2464220A4 (en) 2009-08-13 2014-05-07 Crystal Bioscience Inc Transgenic animal for the production of antibodies with minimal complementarity-determining regions
WO2011056864A1 (en) 2009-11-05 2011-05-12 Anaptysbio, Inc. Methods of generating improved antigen-binding agents using chain shuffling and optionally somatic hypermutation
CA2781159A1 (en) 2009-11-17 2011-05-26 Kyowa Hakko Kirin Co., Ltd. Human artificial chromosome vector
US20120269830A1 (en) 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
KR101553244B1 (ko) 2009-12-10 2015-09-15 리제너론 파마슈티칼스 인코포레이티드 중쇄 항체를 만드는 마우스
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
RU2724663C2 (ru) 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
EP3156062A1 (en) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
CN103228130B (zh) 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
JP6009441B2 (ja) 2010-06-22 2016-10-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ハイブリッド軽鎖マウス
NZ606824A (en) 2010-08-02 2015-05-29 Regeneron Pharma Mice that make binding proteins comprising vl domains
MX338953B (es) 2010-08-16 2016-05-06 Novimmune Sa Metodos para la generacion de anticuerpos multiespecificos y multivalentes.
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
KR20130118925A (ko) 2010-12-22 2013-10-30 제넨테크, 인크. 항-pcsk9 항체 및 사용 방법
PL2578688T5 (pl) 2011-02-25 2023-05-29 Regeneron Pharmaceuticals, Inc. Myszy adam6
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
JP2014533930A (ja) 2011-09-19 2014-12-18 カイマブ・リミテッド 免疫グロブリン遺伝子多様性の操作およびマルチ抗体治療薬
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
SG10202010120XA (en) 2011-10-17 2020-11-27 Regeneron Pharma Restricted immunoglobulin heavy chain mice
US20130102031A1 (en) 2011-10-25 2013-04-25 Anaptysbio, Inc. Use of somatic hypermutation to create insertion and deletion mutations in vitro
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
CA2859408C (en) 2011-12-20 2020-06-16 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
PL2809150T3 (pl) 2012-02-01 2020-04-30 Regeneron Pharmaceuticals, Inc. Humanizowane myszy wykazujące ekspresję łańcuchów ciężkich zawierających domeny VL
CN108101983A (zh) 2012-03-02 2018-06-01 瑞泽恩制药公司 艰难梭状芽孢杆菌毒素的人源抗体
EP3165086A1 (en) 2012-03-06 2017-05-10 Regeneron Pharmaceuticals, Inc. Common light chain mouse
SG10201607727PA (en) 2012-03-16 2016-11-29 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
DK2800811T3 (en) 2012-05-25 2017-07-17 Univ Vienna METHODS AND COMPOSITIONS FOR RNA DIRECTIVE TARGET DNA MODIFICATION AND FOR RNA DIRECTIVE MODULATION OF TRANSCRIPTION
KR102436654B1 (ko) 2012-06-12 2022-08-26 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
SG11201504523UA (en) 2012-12-12 2015-07-30 Broad Inst Inc Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
LT2840892T (lt) 2013-02-20 2018-07-25 Regeneron Pharmaceuticals, Inc. Nežmogaus tipo gyvūnai su modifikuotomis imunoglobulino sunkiųjų grandinių sekomis
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US20150033372A1 (en) 2013-05-01 2015-01-29 Kymab Limited Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US20140331344A1 (en) 2013-05-03 2014-11-06 Kymab Ltd. Transgenic Animals
US20140331339A1 (en) 2013-05-03 2014-11-06 Kymab Limited Transgenic Non-Human Assay Vertebrates, Assays and Kits
SG10201802295XA (en) 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules

Also Published As

Publication number Publication date
WO2013144566A2 (en) 2013-10-03
CN104334732A (zh) 2015-02-04
EP2831244A2 (en) 2015-02-04
HK1200872A1 (en) 2015-08-14
SG11201405058WA (en) 2014-09-26
WO2013061098A3 (en) 2013-06-20
JP2018119012A (ja) 2018-08-02
US20170101483A1 (en) 2017-04-13
US9938357B2 (en) 2018-04-10
WO2013061098A2 (en) 2013-05-02
US20210079118A1 (en) 2021-03-18
CA2867530A1 (en) 2013-10-03
WO2013144566A3 (en) 2013-11-21
US20130263292A1 (en) 2013-10-03
US20230159660A1 (en) 2023-05-25
AU2013239501A1 (en) 2014-09-18
US10774155B2 (en) 2020-09-15
JP6336435B2 (ja) 2018-06-06
US9253965B2 (en) 2016-02-09
JP2020176140A (ja) 2020-10-29
US20170096498A1 (en) 2017-04-06
DK2831244T3 (en) 2018-03-19
EP3366126C0 (en) 2024-05-15
AU2013239501B2 (en) 2018-08-02
US9938358B2 (en) 2018-04-10
CN104334732B (zh) 2018-03-30
EP2785845A2 (en) 2014-10-08
US20180298112A1 (en) 2018-10-18
JP7475415B2 (ja) 2024-04-26
US9924705B2 (en) 2018-03-27
ES2979344T3 (es) 2024-09-25
JP2015512634A (ja) 2015-04-30
NZ629202A (en) 2016-08-26
JP2023009136A (ja) 2023-01-19
US20160219846A1 (en) 2016-08-04
EP3366126A1 (en) 2018-08-29
EP2831244B1 (en) 2018-01-31
EP3366126B1 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
IN2014MN01879A (pl)
WO2015049517A3 (en) Animal models and therapeutic molecules
HK1162119A1 (en) Animal models and therapeutic molecules
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
MX2020001450A (es) Composiciones para reducir la inmunosupresion por celulas de tumor.
NZ700823A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
MY178142A (en) Anti-phf-tau antibodies and their uses
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
EP4324480A3 (en) Anti-transferrin receptor antibodies and methods of use
AU2014236098A8 (en) Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
EA201790175A1 (ru) Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
MX353476B (es) Anticuerpos anti-cxcl13 y metodos para usarlos.
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
MX360368B (es) Regiones de anticuerpo modificado y sus usos.
MX2014004326A (es) Anticuerpos a cd1d.
MX2013002960A (es) Composiciones de anticuerpo y metodos de uso.
WO2012149334A3 (en) Methods and compositions for the generation and use of conformation-specific antibodies
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.
MX2010000979A (es) Metodos y composiciones para tratar enfermedad autoinmune.
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.